^
Association details:
| Biomarker: | RET fusion |
|---|---|
| Cancer: | Thyroid Gland Papillary Carcinoma |
| Drug: | Retevmo (selpercatinib) (RET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Papillary Thyroid Cancer: Consider systemic therapy…Selpercatinib for patients with RET-fusion positive tumor
Title:
The China NMPA Approves Selpercatinib for the Treatment of Patients with RET-driven Lung and Thyroid Cancers
Excerpt:
Innovent Biologics, Inc...is pleased to see that the National Medical Products Administration (NMPA) of China has approved the New Drug Application (NDA) for selpercatinib (40mg & 80mg capsules) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion...
Source:
Title:
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
Excerpt:
...- Participants must have histologically- or cytologically-confirmed follicular-derived nonanaplastic thyroid cancer that is metastatic and/or unresectable AND harbors a known oncogenic RET gene fusion, performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified or equivalently accredited diagnostic laboratory....
Trial ID:
Source:
Title:
A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.
Published date:
05/16/2018
Excerpt:
...RET fusion+ NSCLC and papillary thyroid cancer (PTC), RET-mutant medullary thyroid cancer (MTC)...The ORR in evaluable RET fusion+ pts was...65% (n = 17/26) in NSCLC and 83% (n = 5/6) in PTC.
DOI:
10.1200/JCO.2018.36.15_suppl.102
Trial ID:
